LL-37

Mechanism of action in research models

LL-37 is studied in connective-tissue, extracellular-matrix, and tissue-remodelling research models. Pathways of interest include nitric-oxide/eNOS signalling, VEGFR2-mediated angiogenesis, actin cytoskeletal regulation, fibroblast migration, and inflammatory cytokine modulation. Preclinical models may use tendon fibroblast cultures, endothelial tube-formation assays, or controlled rodent injury models — always within institutional ethical approval.

Combination blends in this category are research preparations designed to study multi-pathway interactions in the same experimental system. HALO does not describe therapeutic outcomes; documentation emphasises identity, purity, and lot traceability for procurement files.

Research background

Connective-tissue peptide research examines how defined sequences influence cell migration, collagen organisation, and growth-factor expression in vitro. LL-37 should be treated as a characterised reference material: verify CAS/sequence on the COA, match lot numbers at receiving, and store lyophilized material per the stability notes below.

Documentation and COA standards

Each HALO lot of LL-37 ships with an independent certificate of analysis documenting:

• HPLC purity — reverse-phase chromatography with ≥98% main peak by area integration
• Identity confirmation — LC-MS, ESI-MS, or MALDI-TOF as applicable to molecular weight
• Lot / batch number — must match the vial label for procurement audit trails
• Test date and method — third-party laboratory, not supplier self-reporting

Read: What is a peptide COA? · Batch-specific verification · Lab results index

Storage and handling

Store lyophilized LL-37 sealed, cold (−20 °C), dry, and protected from light until reconstitution. After reconstitution with an appropriate research diluent, follow institutional stability protocols; minimise freeze-thaw cycles and document open-vial dates in the lab log.

Tools: Peptide calculator · Lyophilized peptide guide · Stability guide